CN117924466A - Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof - Google Patents
Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof Download PDFInfo
- Publication number
- CN117924466A CN117924466A CN202311623596.6A CN202311623596A CN117924466A CN 117924466 A CN117924466 A CN 117924466A CN 202311623596 A CN202311623596 A CN 202311623596A CN 117924466 A CN117924466 A CN 117924466A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 7
- 238000009739 binding Methods 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 238000002965 ELISA Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 230000002055 immunohistochemical effect Effects 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 2
- 206010028748 Nasal obstruction Diseases 0.000 claims description 2
- 206010053159 Organ failure Diseases 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000036071 Rhinorrhea Diseases 0.000 claims description 2
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 26
- 241000700605 Viruses Species 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102100031673 Corneodesmosin Human genes 0.000 description 14
- 101710139375 Corneodesmosin Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 229940125645 monoclonal antibody drug Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 210000001806 memory b lymphocyte Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710137302 Surface antigen S Proteins 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 229940048921 humira Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Food Science & Technology (AREA)
Abstract
The invention relates to a broad-spectrum anti-coronavirus fully human monoclonal antibody and a preparation method and application thereof, and particularly discloses heavy chain and light chain complementarity determining regions and heavy chain and light chain variable region sequences of antibodies 2I3, 3I15 and 4E 17. The antibody of the invention is a humanized antibody, and has low side effect and high affinity and specificity.
Description
The invention is as follows: 202011390806.8, the application date is: the invention discloses a full-humanized monoclonal antibody of SAR-COV-2 and a preparation method and application thereof, which are divisional application of Chinese patent application in year 2020, month 12 and month 02.
Technical Field
The invention belongs to the field of immunology, and particularly relates to an anti-SAR-COV-2 (COVID-19) fully humanized monoclonal antibody, a preparation method and application thereof.
Background
Of the ten global mass-market drugs in 2018, 8 were fully human or humanized monoclonal antibody drugs. The first anti-TNFa monoclonal antibody Humira of Abwe company for treating arthritis is a fully human monoclonal antibody, which is sold for more than 100 hundred million years. Since the first monoclonal antibody drug was marketed in 1986, the monoclonal antibody drug underwent the stages of murine monoclonal antibody drug (e.g., orth @ lone OKT < 3 >, chimeric monoclonal antibody drug (Rituximab), humanized monoclonal antibody drug (Herceptin), and fully human monoclonal antibody drug (Humira). Since the human body has an anti-mouse antibody reaction (HAMA), the mouse monoclonal antibody drug and the chimeric monoclonal antibody drug are gradually eliminated, and the monoclonal antibody drugs currently occupying the market are all humanized monoclonal antibody drugs. Compared with the international advanced humanized antibody production technology, the Shenzhen has a great gap even in China, is mainly represented in the field of humanized antibody medicines, has weak innovation capability and few varieties which are independently researched and developed, has no report of original humanized monoclonal antibody medicines on the market at present, and has huge antibody medicine market occupied by foreign medicine enterprises. The situation of falling behind is changed in China, and the market of antibody medicines at home and abroad with huge consumption potential is striven for overcoming the technology of fully humanized monoclonal antibodies.
The humanized monoclonal antibody has high specific remarkable curative effect in the aspects of treating inflammation, cancer, influenza, especially coronavirus and the like. COVID-19 is an acute respiratory infectious disease caused by a SAR-COV-2 coronavirus, and so far there is still a lack of effective drugs and vaccines. The new coronavirus needs to rely on specific molecules expressed by the virus itself to bind to receptors on human cells when invading the cells in order to infect the cells and further expand. The humanized antibody for neutralizing the virus is a certain specific antibody generated by human B lymphocytes, and can be combined with antigens on the surface of the virus, so that the virus is prevented from adhering to target cell receptors, the virus is prevented from invading cells, and the SAR-COV-2 influenza can be effectively prevented and treated.
Disclosure of Invention
In order to solve the above problems, the present invention provides an antibody against SAR-COV-2 or an antigen binding fragment thereof, which specifically binds to the S protein of SAR-COV-2.
In one aspect, the invention provides an isolated antibody or antigen-binding fragment thereof directed against SAR-COV-2; it Has Complementarity Determining Regions (HCDR) of three heavy chain variable regions and complementarity determining regions (LCDR) of three light chain variable regions of any one of the following groups:
antibody 2E5
2E5-HCDR1：GFTFSTYG SEQ ID No：1；
2E5-HCDR2：IWYDGSSK SEQ ID No：2；
2E5-HCDR3：ARDPKTTVTTKMDV SEQ ID No：3；
2E5-LCDR1：SLRLYY SEQ ID No：4；
2E5-LCDR, 2: DKD; and
2E5-LCDR3：NSRDSSGNHLGVL SEQ ID No：5；
Or alternatively
Antibody 2I3
2I3-HCDR1：GFTFSNHA SEQ ID No：10；
2I3-HCDR2：ISGSDGSA SEQ ID No：11；
2I3-HCDR3：ARGNWESSYAFCDN SEQ ID No：12；
2I3-LCDR1：QSVLYRSNSKNY SEQ ID No：13；
2I3-LCDR, 2: WAS; and
2I3-LCDR3：LQHYSFPFT SEQ ID No：14；
Or alternatively
Antibody 3I15
3I15-HCDR1：GFTLSSYGSEQ ID No：19；
3I15-HCDR2：LGYSGDSI SEQ ID No：20；
3I15-HCDR3：ARLWVASGGDDY SEQ ID No：21；
3I15-LCDR1：QSVSHY SEQ ID No：22；
3I15-LCDR 2: DTS; and
3I15-LCDR3：QQRSIWPLT SEQ ID No：23；
Or alternatively
Antibody 4E17
4E17-HCDR1：GFAFSTYA SEQ ID No：28；
4E17-HCDR2：ISSGSSTI SEQ ID No：29；
4E17-HCDR3：ARGRSYALADLPY SEQ ID No：30；
4E17-LCDR1：QSISSW SEQ ID No：31；
4E17-LCDR, 2: EAS; and
4E17-LCDR3：QQYNSYSSLT SEQ ID No：32。
In another aspect, the invention provides an isolated antibody or antigen binding fragment thereof against SAR-COV-2, wherein the heavy and light chain variable regions of antibody 2E5 are:
2E5 heavy chain variable region:
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWYDGSSKSYADSVKGRFTVSSDDSKNILYLQMNSLRAEDTAVYYCARDPKTTVTTKMDVWGQGTTVTVSS SEQ ID No：6
2E5 light chain variable region:
SSELTQDPAVSVALGQTVRITCQGDSLRLYYANWYQQKPGQAPLLVIYDKDNRPSGIPDRFSGSSSGSTASLTITGAQAEDEADYYCNSRDSSGNHLGVLFGGGTKLTVT SEQ ID No：7;
Or the antibody 2I3 heavy chain variable region and the light chain variable region are:
2I3 heavy chain variable region:
EVQLLESGGGLVQPGGSLRLSCVASGFTFSNHAMTWVRQAPGKGLDWVSTISGSDGSANYADSVKGRVIISRDNSKNTLYLQMNSLRAEDTAVYYCARGNWESSYAFCDNWGQGTLVTVSS SEQ ID No：15
2I3 light chain variable region:
DIVMTQSPFSLPVSLGERATINCKSSQSVLYRSNSKNYLAWYQQKPGQAPKLLIYWASTRKSGVPDRFSASGSGTDFTLTISSLQPEDVADYYCLQHYSFPFTFGPGTKVGLR SEQ ID No:16;
or the antibody 3I15 heavy chain variable region and light chain variable region are:
3I15 heavy chain variable region:
EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYGMSWVRQAPGKGLEWVSGLGYSGDSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARLWVASGGDDYWGQGTLVTVSS SEQ ID No：24
3I15 light chain variable region:
EIVLTQSPATLSLSPGERATLSCRASQSVSHYLAWFQQKSGQAPRLLIYDTSKRATGTPATFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSIWPLTFGGGTKLEIK SEQ ID No:25
or the antibody 4E17 heavy chain variable region and light chain variable region are:
4E17 heavy chain variable region:
EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYAMNWVRQAPGKGLEWVSYISSGSSTIYYANSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRSYALADLPYWGQGTLVTVSS SEQ ID No：33
4E17 light chain variable region:
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSSLTFGGGTKVEIK SEQ ID No:34
In the embodiments of the present invention, the antibody or antigen-binding fragment thereof is a humanized antibody, more preferably a fully humanized antibody.
In the technical scheme of the invention, the antibody is an IgG1 antibody.
In the technical scheme of the invention, the antibody or the antigen binding fragment thereof specifically binds to the SAR-COV-2 surface S protein.
In the technical scheme of the invention, the antibody is a monoclonal antibody or a polyclonal antibody, preferably a monoclonal antibody.
In the technical scheme of the invention, the antibody or the antigen binding fragment thereof specifically binds to the SAR-COV-2 surface S protein.
In a further aspect the invention provides a nucleotide sequence encoding an antibody or antigen binding fragment thereof as hereinbefore described.
In a further aspect, the invention provides a vector comprising a nucleotide sequence as hereinbefore described.
In a further aspect the invention provides a host cell comprising the aforementioned vector or vector set, preferably the host cell is prokaryotic or eukaryotic, more preferably selected from yeast cells, mammalian cells or other cells suitable for the preparation of antibodies or antigen-binding fragments thereof.
In a further aspect the invention provides a kit comprising an antibody or antigen binding fragment thereof as hereinbefore described.
In a further aspect the invention provides a detection reagent comprising an antibody or antigen-binding fragment thereof as hereinbefore described.
In a further aspect the present invention provides the use of an antibody or antigen binding fragment thereof as described above as a detection reagent for: enzyme-linked immunosorbent assay (ELISA), immunoblotting (Western Blot), flow cytometry (FACS), immunohistochemical (IHC) assay, or immuno-PCR.
In the immunological detection described above, the antibody or antigen-binding fragment thereof may be coupled alone or with a conjugate such as a conjugate of horseradish peroxidase (HRP), alkaline Phosphatase (AP), biotin (Biotin), fluorescein Isothiocyanate (FITC), cy3, cy5, magnetic beads, agarose, etc., by electrostatic adsorption or hydrophilic-hydrophobic adsorption.
In the present embodiment, the detection reagent can be used for detection for non-diagnostic or therapeutic purposes.
In a further aspect the invention provides a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof as hereinbefore described and a pharmaceutically acceptable adjuvant.
In a further aspect of the invention, wherein the antibody or antigen binding fragment thereof blocks or reduces binding of the S protein of SAR-COV-2 to a cell surface receptor of the subject, preferably a cell angiotensin converting enzyme related carboxypeptidase (ACE 2).
In a further aspect, the invention provides the use of an antibody or antigen binding fragment thereof against SAR-COV-2 in the manufacture of a medicament for preventing, treating or alleviating at least one symptom or indication of SAR-COV-2 infection.
In the technical scheme of the invention, the medicine is an oral or injection preparation.
In a further aspect, the invention provides a method of preventing, treating or alleviating at least one symptom or indication of a SAR-COV-2 infection, the method comprising administering to a subject an antibody or antigen-binding fragment thereof of any of the preceding or a pharmaceutical composition of the preceding.
In a further aspect of the invention, wherein the at least one symptom or indication is selected from the group consisting of: pulmonary inflammation, alveolar injury, fever, cough, dyspnea, hypoxia, acute respiratory distress syndrome, septic shock, coagulation dysfunction, metabolic acidosis, nasal obstruction, runny nose, sore throat, diarrhea, organ failure, septic shock and death.
In a further embodiment of the invention, the pharmaceutical composition or the antibody or antigen binding fragment thereof is administered in combination with a second therapeutic agent. Wherein the second therapeutic agent is selected from the group consisting of: anti-inflammatory drugs (e.g., corticosteroids and non-steroidal anti-inflammatory drugs), antiviral drugs, different antibodies to the S protein of SAR-COV-2, vaccines for SAR-COV-2, antibiotics, dietary supplements such as antioxidants, and any other palliative therapy for treating SAR-COV-2 infection, drugs that alleviate the symptoms or indications described above.
In a technical aspect of the invention, wherein the pharmaceutical composition or the antibody or antigen binding fragment thereof is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.
Advantageous effects
(1) The anti-SAR-COV-2 antibody disclosed by the invention can be used for targeting and combining the S protein of the SAR-COV-2 virus, has high specificity, and can effectively block the combination of the S protein on the surface of the SAR-COV-2 virus and a receptor on the surface of a cell of a subject.
(2) Compared with the murine antibody, the gene of the fully human antibody is fully derived from human genes, has no other species components, does not generate toxic or side effects such as anti-mouse anti-antibody and the like in human body, has better biocompatibility, and is more suitable and potential to become a macromolecular medicament for treating influenza virus.
(3) Compared with the method for preparing the SAR-COV-2 virus-resistant humanized monoclonal antibody by using the phage display technology provided by the prior art, the method for developing the SAR-COV-2 virus-resistant antibody by using the single B cell has the advantages of simplicity and rapidness in operation, high affinity and specificity of the produced humanized antibody and the like.
Drawings
FIG. 1 is a graph showing ELISA results of example 1.
Detailed Description
The following detailed description of the present invention will be made in detail to make the above objects, features and advantages of the present invention more apparent, but should not be construed to limit the scope of the present invention.
In order to more clearly understand the technical features, objects and advantages of the present invention, the following detailed description of the technical solution of the present invention will be made with reference to specific embodiments, and it should be understood that these examples are only for illustrating the present invention and are not intended to limit the scope of the present invention. In the examples, each of the starting reagent materials is commercially available, and the experimental methods without specifying the specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.
As used herein, the term "antibody" refers to a molecule comprising at least one antigen binding site that immunospecifically binds to a particular antigen target of interest. Thus, the term "antibody" includes, but is not limited to, full length antibodies and/or variants thereof, fragments, peptibodies, and variants thereof, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, human antibodies, humanized antibodies, and antibody mimics of the structure and/or function of an antibody or designated fragments or portions thereof, including single chain antibodies and fragments thereof. Binding of an antibody to a target may cause a variety of effects, such as, but not limited to, modulation, reduction, increase, antagonism, agonism, alleviation, slowing, blocking, inhibition, elimination and/or interference with at least one target activity or binding, or receptor activity or binding, in vitro, in situ and/or in vivo. Thus, antibodies of the present disclosure encompass antibody fragments capable of binding to a biomolecule (e.g., an antigen or receptor) or portion thereof, including but not limited to Fab, fab ' and F (ab ') 2, pFc ', fd, single domain antibodies (sdAb), variable fragments (Fv), single chain variable fragments (scFv), or disulfide-linked Fv (sdFv); a bifunctional antibody or a bivalent bifunctional antibody; a linear antibody; a single chain antibody molecule; multispecific antibodies formed from antibody fragments. Antibodies can be of any type (e.g., igG, igE, igM, igD, igA and IgY), class (e.g., igG1, igG2, igG3, igG4, igA1, and IgA 2) or subclass.
As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for the possible presence of small amounts of mutations that may occur naturally. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to its specificity, monoclonal antibodies have the advantage that they can be synthesized without contaminating other antibodies. The modifier "monoclonal" is not to be construed as requiring antibody production by any particular method.
As used herein, the term HCDR is synonymous with heavy chain complementarity determining region and LCDR is synonymous with light chain complementarity determining region.
As used herein, monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular class or subclass of antibody, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another class or subclass of antibody, and fragments of such antibodies exhibit the desired biological activity.
As used herein, S protein refers to Spike protein (Spike protein) on coronaviruses, and SARS-CoV-2 recognizes ACE2 on the surface of cells in humans through Spike protein on the surface of the virus and infects host cells. The S protein on the surface of coronavirus SARS-CoV-2 can inhibit the adhesion of virus to target cell receptor effectively to prevent virus from invading cell.
The term "humanized antibody" as used herein includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The humanized antibodies of the invention may comprise amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or in vitro site-specific mutagenesis or by in vivo somatic mutation).
The term "antigen-binding fragment" or the like as used herein includes any naturally occurring, enzymatically available, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. The term "antigen binding fragment" of an antibody as used herein has the ability to bind to one or more fragments of the S protein of SAR-COV-2.
In one aspect, the invention provides an anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from the monoclonal antibody capable of specifically binding SAR-COV-2, wherein the amino acid sequences of the heavy and light chain CDR1, CDR2 and CDR3 regions of the antibody are as follows:
antibody 2E5
2E5-HCDR1：GFTFSTYG SEQ ID No：1；
2E5-HCDR2：IWYDGSSK SEQ ID No：2；
2E5-HCDR3：ARDPKTTVTTKMDV SEQ ID No：3；
2E5-LCDR1：SLRLYY SEQ ID No：4；
2E5-LCDR, 2: DKD; and
2E5-LCDR3：NSRDSSGNHLGVL SEQ ID No：5；
Or alternatively
Antibody 2I3
2I3-HCDR1：GFTFSNHA SEQ ID No：10；
2I3-HCDR2：ISGSDGSA SEQ ID No：11；
2I3-HCDR3：ARGNWESSYAFCDN SEQ ID No：12；
2I3-LCDR1：QSVLYRSNSKNY SEQ ID No：13；
2I3-LCDR, 2: WAS; and
2I3-LCDR3：LQHYSFPFT SEQ ID No：14；
Or alternatively
Antibody 3I15
3I15-HCDR1：GFTLSSYGSEQ ID No：19；
3I15-HCDR2：LGYSGDSI SEQ ID No：20；
3I15-HCDR3：ARLWVASGGDDY SEQ ID No：21；
3I15-LCDR1：QSVSHY SEQ ID No：22；
3I15-LCDR 2: DTS; and
3I15-LCDR3：QQRSIWPLT SEQ ID No：23；
Or alternatively
Antibody 4E17
4E17-HCDR1：GFAFSTYA SEQ ID No：28；
4E17-HCDR2：ISSGSSTI SEQ ID No：29；
4E17-HCDR3：ARGRSYALADLPY SEQ ID No：30；
4E17-LCDR1：QSISSW SEQ ID No：31；
4E17-LCDR, 2: EAS; and
4E17-LCDR3：QQYNSYSSLT SEQ ID No：32。
In some embodiments, the heavy chain variable region amino acid sequence of the antibody 2E5 is shown as SEQ ID NO. 7, or the sequence is replaced, deleted or added with one or more amino acids to form an amino acid sequence with the same function;
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWYDGSSKSYADSVKGRFTVSSDDSKNILYLQMNSLRAEDTAVYYCARDPKTTVTTKMDVWGQGTTVTVSS SEQ ID No：6
And is also provided with
The light chain variable region amino acid sequence of the antibody is shown as SEQ ID NO. 7, or the amino acid sequence with the same function formed by replacing, deleting or adding one or more amino acids SSELTQDPAVSVALGQTVRITCQGDSLRLYYANWYQQKPGQAPLLVIYDKDNRPSGIPDRFSGSSSGSTASLTITGAQAEDEADYYCNSRDSSGNHLGVLFGGGTKLTVT SEQ ID No：7.
In some embodiments, the heavy chain variable region amino acid sequence of the antibody 2I3 is shown as SEQ ID NO. 15, or the amino acid sequence with equivalent functions is formed by replacing, deleting or adding one or more amino acids;
EVQLLESGGGLVQPGGSLRLSCVASGFTFSNHAMTWVRQAPGKGLDWVSTISGSDGSANYADSVKGRVIISRDNSKNTLYLQMNSLRAEDTAVYYCARGNWESSYAFCDNWGQGTLVTVSS SEQ ID NO:15
And is also provided with
The light chain variable region amino acid sequence of the antibody is shown as SEQ ID NO. 16, or the sequence is replaced, deleted or added with one or more amino acids to form an amino acid sequence with the same function.
DIVMTQSPFSLPVSLGERATINCKSSQSVLYRSNSKNYLAWYQQKPGQAPKLLIYWASTRKSGVPDRFSASGSGTDFTLTISSLQPEDVADYYCLQHYSFPFTFGPGTKVGLR SEQ ID NO:16.
In some embodiments, the heavy chain variable region amino acid sequence of the antibody 3I15 is shown as SEQ ID NO. 24, or the amino acid sequence with equivalent functions is formed by replacing, deleting or adding one or more amino acids;
EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYGMSWVRQAPGKGLEWVSGLGYSGDSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARLWVASGGDDYWGQGTLVTVSS SEQ ID NO:24
And is also provided with
The light chain variable region amino acid sequence of the antibody is shown as SEQ ID NO. 25, or the amino acid sequence with the same function formed by replacing, deleting or adding one or more amino acids
EIVLTQSPATLSLSPGERATLSCRASQSVSHYLAWFQQKSGQAPRLLIYDTSKRATGTPATFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSIWPLTFGGGTKLEIK SEQ ID NO:25.
In some embodiments, the heavy chain variable region amino acid sequence of the antibody 4E17 is shown as SEQ ID NO. 33, or the amino acid sequence with equivalent functions is formed by replacing, deleting or adding one or more amino acids;
EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYAMNWVRQAPGKGLEWVSYISSGSSTIYYANSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRSYALADLPYWGQGTLVTVSS SEQ ID NO:33
And is also provided with
The light chain variable region amino acid sequence of the antibody is shown as SEQ ID NO. 34, or the amino acid sequence with the same function formed by replacing, deleting or adding one or more amino acids
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSSLTFGGGTKVEIK SEQ ID NO:34.
ELISA experiments prove that the anti-SAR-COV-2 fully human monoclonal antibody can target and bind the S protein of SAR-COV-2 virus. Compared with the murine antibody, the gene of the fully human antibody is fully derived from human genes, has no other species components, does not generate toxic or side effects such as anti-mouse anti-antibody and the like in human body, has better biocompatibility, and is more suitable and potential to become a macromolecular medicament for treating influenza virus.
In another aspect, the invention provides a gene encoding an anti-SAR-COV-2 fully human monoclonal antibody of the invention. In some embodiments, the gene comprises a nucleotide sequence encoding an amino acid having the above-described amino acids.
In some embodiments, the nucleotide sequence is as follows (the following sequences are merely exemplary, and one skilled in the art can design other nucleotide sequences that can be translated into the desired amino acid sequence depending on the particular amino acid sequence):
the nucleotide sequence encoding the antibody 2E5 heavy chain variable region is:
CagGTGCagctggtggagtctgggggaggcgtggtccagcctgggaggtccctgagactctcctgtgcagcctctggattcaccttcagtacctatggcatgcactgggtccgccaggctccaggcaaggggctggagtgggtggcagttatatggtatgatggaagtagtaaatcctatgcagactccgtgaagggccgattcaccgtctccagcgacgattccaagaatatattgtatctgcaaatgaacagcctgagagccgaggacacggctgtctattactgtgcgagagatccaaagacaacggtgactacaaaaatggacgtctggggccaagggaccacggtcaccgtctcctcaSEQ ID No：8
The nucleotide sequence encoding the antibody 2E5 light chain variable region is:
tcgtctgagctgactcaggaccctgctgtgtctgtggccttgggacagacagtcaggatcacatgccaaggagacagcctcagactctattatgcaaactggtaccaacagaagccaggacaggcccctctacttgtcatctatgataaagacaaccggccctcagggatcccagaccgattctctggctccagctcaggaagcacagcttccttgaccatcactggggctcaggcggaagatgaggctgactattactgtaactcccgggacagcagtggtaaccatctgggggttctcttcggcggcgggaccaagctgaccgtcacagta SEQ ID No：9.
The nucleotide sequence encoding the heavy chain variable region of antibody 2I3 is:
gaggtgcagctgttggagtctgggggaggcctggtgcagccgggggggtccctgagactctcctgtgtcgcctctggattcacctttagcaaccatgccatgacgtgggtccgccaggctccaggaaagggactggattgggtctcaactataagcggcagtgatggaagcgcaaattacgcagactccgtgaagggccgggttatcatctccagagacaattccaagaacacactgtatctgcaaatgaacagcctgagagccgaagacacggccgtatattactgtgcgagggggaattgggagagttcttatgccttctgtgataactggggccagggaaccctggtcaccgtctcctca SEQ ID No：17
The nucleotide sequence encoding the light chain variable region of antibody 2I3 is:
gacAtcgTgatgacccagtctccattctccctgcctgtgtctctgggcgagagggccaccatcaactgcaagtccagccagagtgttttatacaggtccaacagtaagaactacttagcttggtatcagcagaaaccaggacaggctcctaagttgctcatttactgggcctctacccgtaaatccggggtccctgaccgattcagtgccagcgggtctgggacagatttcactctcaccataagcagcctgcaacctgaggatgtggcagattattactgccttcaacattatagttttcctttcacttttggccctgggaccaaagtgggcctcaga SEQ ID No：18.
the nucleotide sequence encoding the heavy chain variable region of antibody 3I15 is:
GaGgtgcagctggtggagtctgggggaggcttggtacagcctggggggtcccttagactctcctgtgcagcctctggattcacccttagttcctatggcatgagttgggtccgccaggctccagggaaggggctggagtgggtctcaggccttggttatagtggtgatagtatatactacgcagactccgtgaagggccggttcaccatctccagagacaattccaagaacacgctgtatctccaaatgaacagcctgagagccgcggacacggccgtatattattgtgcgagactttgggtcgcaagtggtggagatgactactggggccagggaaccctggtcaccgtctcctca SEQ ID No：26
the nucleotide sequence encoding the light chain variable region of antibody 3I15 is:
gaAatTgTgTtgaCacagtctccaGCcAccctgtcgttgtctccaggggagagagccaccctctcctgcagggccagtcagagtgttagccactacttagcgtggtttcaacagaaatctggccaggctcccaggctcctcatctatgatacatccaagagggccactggcaccccagccacattcagtggcagtgggtctgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcggtttattactgccagcagcgtagcatctggcctctcactttcggcggagggaccaaactggagatcaaa SEQ ID No：27.
The nucleotide sequence encoding the heavy chain variable region of antibody 4E17 is:
gaggtgcagctggtggagtctgggggaggcttggtacagcctggggggtccctgagactctcctgtgcagcctctggattcgccttcagtacctatgccatgaactgggtccgccaggctccagggaaggggctggagtgggtttcatacattagtagtggtagtagtaccatatactacgcaaactctgtgaagggccgattcaccatctccagagacaacgccaagaactcactgtatctgcaaatgaacagcctgagagccgaggacacggctgtgtattactgtgcgagaggtcggagttacgcattagctgacttgccgtactggggccagggaaccctggtcaccgtctcctca SEQ ID No：35
the nucleotide sequence encoding the light chain variable region of antibody 4E17 is:
gacatccAgatgaCccagtctccatccaccctgtctgcatctgtaggagacagagtcaccatcacttgccgggccagtcagagtattagtagctggttggcctggtatcagcagaaaccagggaaagcccctaagctcctgatctatgaggcgtctagtttagaaagtggggtcccatcaaggttcagcggcagtggatctgggacagaattcactctcaccatcagcagcctgcagcctgatgactttgcaacttattactgccaacagtataatagttattcttcgctcactttcggcggagggaccaaggtggagatcaaacga SEQ ID No：36.
in the heavy chain variable region and light chain variable region sequences of the antibodies of the invention, CDR regions are shown in the underlined regions.
In another aspect, the invention provides a vector comprising a gene as described above.
In a further aspect, the invention provides a cell comprising a gene as described above or a vector as described above.
In still another aspect, the present invention provides a method for producing the anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from the monoclonal antibody capable of specifically binding SAR-COV-2, the method comprising culturing genetically engineered cells containing the above gene encoding the heavy and light chain of the anti-SAR-COV-2 fully human monoclonal antibody or the above vector or directly culturing the above cells, collecting and purifying the anti-SAR-COV-2 fully human monoclonal antibody.
In the prior art, a method for preparing the anti-SAR-COV-2 virus humanized monoclonal antibody by adopting a phage display technology has the advantages of low production cost, no complicated work such as immunization and cell fusion, and the like, but has obvious disadvantages that the antibodies obtained from a non-immune antibody library often have insufficient affinity, are limited by the conversion rate of exogenous genes, have insufficient library capacity of the antibody library to cover the antibody diversity of animals, and the like. The invention separates the B cell secreting functional antibody from the blood of patient, then extracts RNA and synthesizes cDNA, clones the gene secreting target antibody from it, and finally recombines and expresses fully human monoclonal antibody. The technology is simple and quick to operate, the produced humanized antibody has high affinity and specificity, and in addition, the improved monoclonal antibody technology with the virus neutralization function or tumor killing function can be further separated from memory B cells, so that complicated operation and cost are greatly reduced.
In another aspect, the invention provides a pharmaceutical composition comprising an anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from the monoclonal antibody capable of specifically binding SAR-COV-2.
In another aspect, the invention provides the use of said anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from said monoclonal antibody capable of specifically binding SAR-COV-2 or said pharmaceutical composition in the manufacture of a medicament for the treatment of a disease caused by SAR-COV-2 virus.
In another aspect, the invention provides a kit for detecting SAR-COV-2 virus levels, comprising the anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from the monoclonal antibody capable of specifically binding SAR-COV-2; in some embodiments, the kit further comprises a second antibody and an enzyme or fluorescent or radiolabel for detection, and a buffer; the second antibody is, for example, an anti-antibody against the monoclonal antibody of the invention.
In order to more clearly understand the technical features, objects and advantages of the present invention, the following detailed description of the technical solution of the present invention will be made with reference to specific embodiments, and it should be understood that these examples are only for illustrating the present invention and are not intended to limit the scope of the present invention. In the examples, each of the starting reagent materials is commercially available, and the experimental methods without specifying the specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.
Example 1
(1) Construction of NTH-3T3 cell line stably expressing CD40L (3T 3-CD 40L)
3T3-CD40L feeder cells were established using lentiviruses. Lentiviral expression vector pLVX-CD40L was constructed, 293T cells were transfected, and viral supernatants were collected on day four of transfection. NIH-3T3 cells were activated, cultured for 3 passages, infected with lentivirus, and cultured and passaged 3 additional times. Cells with FITC fluorescence intensity near MFI were sorted using a flow cytometer, re-added to a flask, incubated and examined in a 5% co 2 incubator at 37 ℃ by staining 3T3 cells expressing CD40L and 3T3 cells transfected with empty vector pLVX (with ZxGreen) with anti-CD 40L with APC, respectively, and then analyzed by flow cytometry. As a result, it was found that all 3T3-CD40L feeder cells expressed CD40L. When the cells grow to 80% -90%, the cells are digested and collected, and the concentration is 1×10 7 cells per milliliter. Placing into a radiometer for 5000rads radiation, re-suspending cells with frozen stock solution at a concentration of 3.5X10 7 cells per mL, sub-packaging 1mL in a freezing small tube, and freezing with liquid nitrogen (2 years storage can be achieved).
(2) Sorting and activation of memory B cells
PBMC of a rehabilitation patient infected with SAR-COV-2 virus are separated and frozen by using a lymph separating liquid, and 10-50X 10 6 cells per tube are frozen in a liquid nitrogen tank. PBMC flow-type staining solution was prepared, and the composition thereof is shown in Table 1 below
TABLE 1 PBMC flow-through staining solution
| Antibodies to | Volume (mu L) |
| CD19-PE-Cy7 | 0.5 |
| IgM-PE | 1.0 |
| IgA-APC | 2.5 |
| IgD-FITC | 2.5 |
| PBS-1％(wt/vol)BSA | 43.5 |
Thawing PBMC, adding the PBMC flow staining solution, sorting by flow cytometry to obtain memory B cells of CD19IgM –IgA–IgD–, and repeating the sorting process if the cell purity is more than 90% and less than 90%. A mixed medium for activating B cells was prepared as shown in table 2 below:
TABLE 2
| Component (A) | Volume of |
| Complete IMDM medium | 336mL |
| IL-2(10,000U mL-1) | 3.5mL |
| IL-21(100μg mL-1) | 175μL |
| 3T3-CD40L obtained in step (1) | 10mL |
Memory B cells are added into a mixed culture medium, mixed evenly and diluted in 384-well plates, 1 cell per well has a volume of 50 μl, and the mixture is placed in a culture box with 5% CO 2 for static culture. After 13 days, the supernatant was subjected to ELISA to obtain a humanized monoclonal antibody.
(3) Surface antigen S protein experiment of human monoclonal antibody combined with SAR-COV-2 virus
The surface antigen S protein is purchased from Yinqiao Shenzhou company, has immunogenicity, and the anti-S protein antibody can be used for SAR-COV-2 influenza virus. ELISA experiments were performed on the supernatant humanized monoclonal antibodies obtained above, specifically:
(1) 100ng/100 μl of HA protein of SAR-COV-2 virus was coated in 96-well ELISA plates, 100 μl per well;
(2) Placing in a refrigerator at 4 ℃ overnight;
(3) Washing with PBST solution three times, adding 200 μl of 5% skimmed milk powder solution into each well, and incubating for 1 hr at 37 ℃;
(4) Three times with PBST solution, 100. Mu.l of normal human serum (negative control) or supernatant without virus infection was added, each three replicates;
(5) After incubation for 1 hour at 37 ℃ the cells were washed three times with PBST solution;
(6) HRP-loaded anti-human IgG antibody (abcam) was diluted 1:5000 and added to the microplate at 100. Mu.L per well;
(7) After incubation for 1 hour at 37 ℃ the cells were washed three times with PBST solution;
(8) 100. Mu.L of TMB substrate solution (Thermo Scientific) was added to each well, at 37℃for 5 min;
(9) 100 μl of 2M sulfuric acid was added to each well, and the absorbance was immediately measured at 450nm in a microplate reader. The results are shown in figure 1, and ELISA experiments show that the human monoclonal antibody obtained by the invention can target and bind the S protein of SAR-COV-2 virus.
EXAMPLE 2 cloning of humanized monoclonal antibody Gene
The B cells obtained in example 1 capable of secreting an antibody binding to SAR-COV-2 virus were lysed, and the lysate was subjected to reverse transcription of RNA to obtain PCR template cDNA of the humanized antibody gene. Primers for cloning antibody genes were designed and synthesized, and the heavy and light chain genes of the antibodies were cloned using cDNA as a template, and sequenced by Jinwei corporation. Specifically:
(1) The lysed B cell fluid was transferred to a 96-well plate (Eppendorf, 030133366).
(2) Reverse transcription system: 150ng random primer (invitrogen,48190-011),0.5μL 10mM dNTP(Invitrogen,18427-088),1μL 0.1M DTT(Invitrogen,18080-044),0.5％v/v Igepal CA-630(Sigma,I3021-50ML),4U RNAsin(Promega),6U Prime RNAse Inhibitor(Eppendorf)and 50UIII REVERSE TRANSCRIPTASE (Invitrogen, 18080-044) was supplemented with DEPC water to 14. Mu.L/well.
(3) Reverse transcription reaction procedure: 42 ℃ for 10min;25 ℃ for 10min;50 ℃ for 60min;94℃for 5min.
(4) The cDNA was stored at-20 ℃.
(5) Primer design and synthesis:
(6) Heavy and light chains of antibody genes were amplified by PCR using KOD-Plus-Neo (TOYOBO, KOD 401) kit, 40. Mu.L system: 3.5. Mu.L cDNA,20nM mix primer, 4. Mu.L buffer, 4. Mu.L 2mM dNTPs, 2.4. Mu.L MgSO 4, 1. Mu.L KOD.
(7) The reaction procedure: 94 ℃ for 2min;45 cycles: 98 ℃ for 10s;58 ℃ for 30s;68℃for 28s.
(8) Agarose gel was performed on the amplified product.
(9) The sequencing result of the antibody gene heavy chain variable region PCR product is as follows, wherein:
the nucleotide sequence of the heavy chain variable region of the antibody 2E5 is shown as SEQ ID No. 8:
CagGTGCagctggtggagtctgggggaggcgtggtccagcctgggaggtccctgagactctcctgtgcagcctctggattcaccttcagtacctatggcatgcactgggtccgccaggctccaggcaaggggctggagtgggtggcagttatatggtatgatggaagtagtaaatcctatgcagactccgtgaagggccgattcaccgtctccagcgacgattccaagaatatattgtatctgcaaatgaacagcctgagagccgaggacacggctgtctattactgtgcgagagatccaaagacaacggtgactacaaaaatggacgtctggggccaagggaccacggtcaccgtctcctcaSEQ ID No：8;
The amino acid sequence of the heavy chain variable region of the antibody 2E5 is shown as SEQ ID No. 6:
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWYDGSSKSYADSVKGRFTVSSDDSKNILYLQMNSLRAEDTAVYYCARDPKTTVTTKMDVWGQGTTVTVSS SEQ ID No：6;
The nucleotide sequence of the light chain variable region of the antibody 2E5 is shown as SEQ ID No. 9,
tcgtctgagctgactcaggaccctgctgtgtctgtggccttgggacagacagtcaggatcacatgccaaggagacagcctcagactctattatgcaaactggtaccaacagaagccaggacaggcccctctacttgtcatctatgataaagacaaccggccctcagggatcccagaccgattctctggctccagctcaggaagcacagcttccttgaccatcactggggctcaggcggaagatgaggctgactattactgtaactcccgggacagcagtggtaaccatctgggggttctcttcggcggcgggaccaagctgaccgtcacagta SEQ ID No：9;
The amino acid sequence of the antibody 2E5 light chain variable region is shown as SEQ ID No. 7
SSELTQDPAVSVALGQTVRITCQGDSLRLYYANWYQQKPGQAPLLVIYDKDNRPSGIPDRFSGSSSGSTASLTITGAQAEDEADYYCNSRDSSGNHLGVLFGGGTKLTVT SEQ ID No：7.
The nucleotide sequence of the heavy chain variable region of the antibody 2I3 is shown as SEQ ID No. 17:
gaggtgcagctgttggagtctgggggaggcctggtgcagccgggggggtccctgagactctcctgtgtcgcctctggattcacctttagcaaccatgccatgacgtgggtccgccaggctccaggaaagggactggattgggtctcaactataagcggcagtgatggaagcgcaaattacgcagactccgtgaagggccgggttatcatctccagagacaattccaagaacacactgtatctgcaaatgaacagcctgagagccgaagacacggccgtatattactgtgcgagggggaattgggagagttcttatgccttctgtgataactggggccagggaaccctggtcaccgtctcctca SEQ ID No：17;
the amino acid sequence of the heavy chain variable region of the antibody 2I3 is shown as SEQ ID No. 15
EVQLLESGGGLVQPGGSLRLSCVASGFTFSNHAMTWVRQAPGKGLDWVSTISGSDGSANYADSVKGRVIISRDNSKNTLYLQMNSLRAEDTAVYYCARGNWESSYAFCDNWGQGTLVTVSS SEQ ID NO:15;
The nucleotide sequence of the light chain variable region of the antibody 2I3 is shown as SEQ ID No. 18,
gacAtcgTgatgacccagtctccattctccctgcctgtgtctctgggcgagagggccaccatcaactgcaagtccagccagagtgttttatacaggtccaacagtaagaactacttagcttggtatcagcagaaaccaggacaggctcctaagttgctcatttactgggcctctacccgtaaatccggggtccctgaccgattcagtgccagcgggtctgggacagatttcactctcaccataagcagcctgcaacctgaggatgtggcagattattactgccttcaacattatagttttcctttcacttttggccctgggaccaaagtgggcctcaga SEQ ID No：18;
The amino acid sequence of the light chain variable region of the antibody 2I3 is shown as SEQ ID No. 16
DIVMTQSPFSLPVSLGERATINCKSSQSVLYRSNSKNYLAWYQQKPGQAPKLLIYWASTRKSGVPDRFSASGSGTDFTLTISSLQPEDVADYYCLQHYSFPFTFGPGTKVGLR SEQ ID NO:16.
The nucleotide sequence of the heavy chain variable region of the antibody 3I15 is shown as SEQ ID No. 26:
GaGgtgcagctggtggagtctgggggaggcttggtacagcctggggggtcccttagactctcctgtgcagcctctggattcacccttagttcctatggcatgagttgggtccgccaggctccagggaaggggctggagtgggtctcaggccttggttatagtggtgatagtatatactacgcagactccgtgaagggccggttcaccatctccagagacaattccaagaacacgctgtatctccaaatgaacagcctgagagccgcggacacggccgtatattattgtgcgagactttgggtcgcaagtggtggagatgactactggggccagggaaccctggtcaccgtctcctca SEQ ID No：26;
The amino acid sequence of the heavy chain variable region of the antibody 3I15 is shown as SEQ ID No. 24
EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYGMSWVRQAPGKGLEWVSGLGYSGDSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARLWVASGGDDYWGQGTLVTVSS SEQ ID NO:24;
The nucleotide sequence of the light chain variable region of the antibody 3I15 is shown as SEQ ID No. 27,
gaAatTgTgTtgaCacagtctccaGCcAccctgtcgttgtctccaggggagagagccaccctctcctgcagggccagtcagagtgttagccactacttagcgtggtttcaacagaaatctggccaggctcccaggctcctcatctatgatacatccaagagggccactggcaccccagccacattcagtggcagtgggtctgggacagacttcactctcaccatcagcagcctagagcctgaagattttgcggtttattactgccagcagcgtagcatctggcctctcactttcggcggagggaccaaactggagatcaaa SEQ ID No：27;
The amino acid sequence of the light chain variable region of the antibody 3I15 is shown as a sequence of SEQ ID No. 25.
EIVLTQSPATLSLSPGERATLSCRASQSVSHYLAWFQQKSGQAPRLLIYDTSKRATGTPATFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSIWPLTFGGGTKLEIK SEQ ID NO:25.
The nucleotide sequence of the heavy chain variable region of the antibody 4E17 is shown as SEQ ID No. 35:
gaggtgcagctggtggagtctgggggaggcttggtacagcctggggggtccctgagactctcctgtgcagcctctggattcgccttcagtacctatgccatgaactgggtccgccaggctccagggaaggggctggagtgggtttcatacattagtagtggtagtagtaccatatactacgcaaactctgtgaagggccgattcaccatctccagagacaacgccaagaactcactgtatctgcaaatgaacagcctgagagccgaggacacggctgtgtattactgtgcgagaggtcggagttacgcattagctgacttgccgtactggggccagggaaccctggtcaccgtctcctca SEQ ID No：35;
The amino acid sequence of the heavy chain variable region of the antibody 4E17 is shown as SEQ ID No. 33
EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYAMNWVRQAPGKGLEWVSYISSGSSTIYYANSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRSYALADLPYWGQGTLVTVSS SEQ ID NO:33;
The nucleotide sequence of the light chain variable region of the antibody 4E17 is shown as SEQ ID No. 36,
gacatccAgatgaCccagtctccatccaccctgtctgcatctgtaggagacagagtcaccatcacttgccgggccagtcagagtattagtagctggttggcctggtatcagcagaaaccagggaaagcccctaagctcctgatctatgaggcgtctagtttagaaagtggggtcccatcaaggttcagcggcagtggatctgggacagaattcactctcaccatcagcagcctgcagcctgatgactttgcaacttattactgccaacagtataatagttattcttcgctcactttcggcggagggaccaaggtggagatcaaacga SEQ ID No：36;
The amino acid sequence of the antibody 4E17 light chain variable region is shown as SEQ ID No. 34
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSSLTFGGGTKVEIK SEQ ID NO:34.
Correspondingly, the CDR region sequences of each antibody are as follows:
antibody 2E5
2E5-HCDR1：GFTFSTYG SEQ ID No：1；
2E5-HCDR2：IWYDGSSK SEQ ID No：2；
2E5-HCDR3：ARDPKTTVTTKMDV SEQ ID No：3；
2E5-LCDR1：SLRLYY SEQ ID No：4；
2E5-LCDR, 2: DKD; and
2E5-LCDR3：NSRDSSGNHLGVL SEQ ID No：5；
Or alternatively
Antibody 2I3
2I3-HCDR1：GFTFSNHA SEQ ID No：10；
2I3-HCDR2：ISGSDGSA SEQ ID No：11；
2I3-HCDR3：ARGNWESSYAFCDN SEQ ID No：12；
2I3-LCDR1：QSVLYRSNSKNY SEQ ID No：13；
2I3-LCDR, 2: WAS; and
2I3-LCDR3：LQHYSFPFT SEQ ID No：14；
Or alternatively
Antibody 3I15
3I15-HCDR1：GFTLSSYGSEQ ID No：19；
3I15-HCDR2：LGYSGDSI SEQ ID No：20；
3I15-HCDR3：ARLWVASGGDDY SEQ ID No：21；
3I15-LCDR1：QSVSHY SEQ ID No：22；
3I15-LCDR 2: DTS; and
3I15-LCDR3：QQRSIWPLT SEQ ID No：23；
Or alternatively
Antibody 4E17
4E17-HCDR1：GFAFSTYA SEQ ID No：28；
4E17-HCDR2：ISSGSSTI SEQ ID No：29；
4E17-HCDR3：ARGRSYALADLPY SEQ ID No：30；
4E17-LCDR1：QSISSW SEQ ID No：31；
4E17-LCDR, 2: EAS; and
4E17-LCDR3：QQYNSYSSLT SEQ ID No：32。
The above results show that the supernatant contains an antibody capable of binding SAR-COV-2 virus.
The last explanation is: the above embodiments are only for illustrating the implementation procedure and features of the present invention, and not for limiting the technical solution of the present invention, and although the present invention has been described in detail with reference to the above embodiments, it should be understood by those of ordinary skill in the art that: modifications and equivalents may be made thereto without departing from the spirit and scope of the invention, and any modifications and equivalents are intended to be included within the scope of the present invention.
Claims (11)
1. An isolated antibody against SAR-COV-2, or an antigen-binding fragment thereof, having three heavy chain complementarity determining regions and three light chain complementarity determining regions as follows:
Antibody 3I15
3I15-HCDR1：GFTLSSYG SEQ ID No：19；
3I15-HCDR2：LGYSGDSI SEQ ID No：20；
3I15-HCDR3：ARLWVASGGDDY SEQ ID No：21；
3I15-LCDR1：QSVSHY SEQ ID No：22；
3I15-LCDR 2: DTS; and
3I15-LCDR3：QQRSIWPLT SEQ ID No：23。
2. The isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof according to claim 1, the heavy chain variable region and the light chain variable region of antibody 3I15 having the sequence of, respectively;
3I15 heavy chain variable region:
EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYGMSWVRQAPGKGLEWVSGLGYSGDSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAADTAVYYCARLWVASGGDDYWGQGTLVTVSS SEQ ID NO:24,
3I15 light chain variable region
EIVLTQSPATLSLSPGERATLSCRASQSVSHYLAWFQQKSGQAPRLLIYDTSKRATGTPATFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSIWPLTFGGGTKLEIK SEQ ID NO:25.
3. The antibody or antigen-binding fragment thereof of any one of claim 1 or claim 2, which is a humanized antibody or antigen-binding fragment thereof.
4. A nucleotide sequence characterized by: encoding the antibody or antigen binding fragment thereof of any one of claims 1-3.
5. A carrier, characterized in that: comprising the nucleotide sequence of claim 4.
6. A host cell, characterized in that: comprising the vector of claim 5.
7. A kit comprising the antibody or antigen-binding fragment thereof of any one of claims 1-3.
8. A detection reagent comprising the antibody or antigen-binding fragment thereof of any one of claims 1-3.
9. Use of the antibody or antigen binding fragment thereof of any one of claims 1-3 as a detection reagent for: enzyme-linked immunosorbent assay, immunoblotting, flow cytometry, immunohistochemical assay, or immuno-PCR.
10. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of any one of claims 1-3 and a pharmaceutically acceptable adjuvant.
11. Use of an antibody or antigen-binding fragment thereof against SAR-COV-2 according to any one of claims 1-3, or a pharmaceutical composition according to claim 10, in the manufacture of a medicament for preventing, treating or alleviating at least one symptom or indication of SAR-COV-2 infection;
preferably, the at least one symptom or indication is selected from the group consisting of: pulmonary inflammation, alveolar injury, fever, cough, dyspnea, hypoxia, acute respiratory distress syndrome, septic shock, coagulation dysfunction, metabolic acidosis, nasal obstruction, runny nose, sore throat, diarrhea, organ failure, septic shock and death.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311623596.6A CN117924466A (en) | 2020-12-02 | 2020-12-02 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011390806.8A CN114573690B (en) | 2020-12-02 | 2020-12-02 | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
| CN202311623596.6A CN117924466A (en) | 2020-12-02 | 2020-12-02 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011390806.8A Division CN114573690B (en) | 2020-12-02 | 2020-12-02 | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117924466A true CN117924466A (en) | 2024-04-26 |
Family
ID=81768828
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311623600.9A Pending CN117924467A (en) | 2020-12-02 | 2020-12-02 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
| CN202311623596.6A Pending CN117924466A (en) | 2020-12-02 | 2020-12-02 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
| CN202011390806.8A Active CN114573690B (en) | 2020-12-02 | 2020-12-02 | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311623600.9A Pending CN117924467A (en) | 2020-12-02 | 2020-12-02 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011390806.8A Active CN114573690B (en) | 2020-12-02 | 2020-12-02 | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN117924467A (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111592594B (en) * | 2020-03-13 | 2022-05-10 | 北京大学 | Monoclonal antibody for resisting novel coronavirus and application thereof |
| CN111620945B (en) * | 2020-05-09 | 2021-01-15 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | Monoclonal antibody or derivative thereof for resisting novel coronavirus |
| CN111995676B (en) * | 2020-05-15 | 2021-03-09 | 潍坊医学院 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
| CN111718411B (en) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 1F2 for resisting SARS-CoV-2 |
| CN111690059B (en) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 1D7 for resisting SARS-CoV-2 |
-
2020
- 2020-12-02 CN CN202311623600.9A patent/CN117924467A/en active Pending
- 2020-12-02 CN CN202311623596.6A patent/CN117924466A/en active Pending
- 2020-12-02 CN CN202011390806.8A patent/CN114573690B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114573690A (en) | 2022-06-03 |
| CN117924467A (en) | 2024-04-26 |
| CN114573690B (en) | 2023-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111620945B (en) | Monoclonal antibody or derivative thereof for resisting novel coronavirus | |
| CN107353340B (en) | anti-H7N 9 fully human monoclonal antibody 2L11, and preparation method and application thereof | |
| CN112574300B (en) | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof | |
| CN101374944B (en) | Methods for obtaining immortalized antibody secreting cells | |
| US20210171611A1 (en) | Antibody that binds to envelope glycoprotein of sever fever with thrombocytopenia syndrome virus and use for same | |
| JP5475774B2 (en) | Human cytomegalovirus neutralizing antibody and use thereof | |
| JP2016020334A (en) | Dengue virus neutralizing antibodies and use thereof | |
| TWI811716B (en) | Methods of treating inflammatory diseases | |
| KR20230166096A (en) | CLDN18.2 antigen binding protein and its applications | |
| EP4357365A1 (en) | Antibody targeting axl protein and antigen binding fragment thereof, and preparation method therefor and application thereof | |
| EP4032906A1 (en) | Methods of treating diseases | |
| WO2021248276A1 (en) | Anti-sar-cov-2 antibody or antigen-binding fragment thereof and use thereof | |
| EP2855524B1 (en) | Novel il-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of il-3 | |
| WO2021258625A1 (en) | Anti-sar-cov-2 (covid-19) fully humanized monoclonal antibody, and preparation method therefor and application thereof | |
| CN117924466A (en) | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof | |
| WO2023092739A1 (en) | Anti-sar-cov-2 fully humanized monoclonal antibody 6g18 and preparation method therefor and application thereof | |
| WO2023070310A1 (en) | Anti-sar-cov-2 fully humanized monoclonal antibody and preparation method therefor and application thereof | |
| WO2021115404A1 (en) | Anti-cd38 antibody and use thereof | |
| CN109957011B (en) | Fully human monoclonal antibody 6E9 against H7N9, and preparation method and application thereof | |
| CN116023475A (en) | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof | |
| CN109957012B (en) | Fully human monoclonal antibody 8E17 against H7N9, and preparation method and application thereof | |
| CN113831409B (en) | anti-SAR-COV-2 antibody or antigen binding fragment thereof and application thereof | |
| EP4206227A1 (en) | Anti-ox40 antibody, and pharmaceutical composition and application thereof | |
| US20240209104A1 (en) | Anti-ox40 antibody, and pharmaceutical composition and application thereof | |
| CN109957013B (en) | Fully human monoclonal antibody 7O2 for resisting H7N9, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |